Signal transduction pathways involved in non-genomic action of estrone on vascular tissue.
Previously we demonstrated that estrone non-genomically regulates rat aortic NOS and COX activity and that this effect depends on ovarian activity. The purpose of the present study was to characterize this effect and investigate the participation of phospholipase C and phophatidylinositol-3-kinase system in the intracellular transduction pathway involved in the response. Using aortic strips isolated from female fertile rats we showed that estrone stimulate nitric oxide synthase and cyclooxygenase in a short time interval (5-20 min), and that NO production was dependent in part on PGI2 production since 1 microM indomethacin significantly reduced this free radical production. Injection of 17-beta-estradiol to ovariectomized rats restored tissue capacity to rapidly increase NO production in response to "in vitro" treatment with 1 nM estrone. We also demonstrated that in aortic strips isolated from intact animals estrone elicited a rapid phospholipase C activation, inducing a biphasic increase in diacylglycerol generation (peaking at 45 s and 5 min). The presence of protein kinase C inhibitor chelerythrine did not prevent the increase of NO released in response to hormone treatment. We proved that PI3K-Akt system does not mediate NOS and COX activation. However, PLC activation was dependent on PI3K since presence of LY 294002 in the incubation medium abolished estrone-induced DAG increment. We concluded that, estrone rapid action on vascular tissue involves a cross talk between NOS and COX system, and the activation of PLC/DAG/PKC transduction pathways.
Massheimer
Virginia
V
Cátedra de Análisis Clínicos II, Departamento de Biología, Bioquímica y Farmacia, Universidad Nacional del Sur., San Juan 670, B8000ICN Bahía Blanca, Argentina. massheim@uns.edu.ar
Polini
Nélida
N
Alvarez
Cristina
C
Benozzi
Silvia
S
Rauschemberger
María Belén
MB
Sellés
Juana
J
D000470:Alkaloids / Q000494:pharmacology; D000818:Animals; D001011:Aorta / Q000187:drug effects* / Q000201:enzymology / Q000378:metabolism; D053119:Benzophenanthridines / Q000494:pharmacology; D004789:Enzyme Activation; D011464:Epoprostenol / Q000096:biosynthesis; D004970:Estrone / Q000494:pharmacology*; D005260:Female; D066298:In Vitro Techniques; D009569:Nitric Oxide / Q000096:biosynthesis; D052248:Nitric Oxide Synthase Type I / Q000378:metabolism; D019869:Phosphatidylinositol 3-Kinases / Q000378:metabolism; D011451:Prostaglandin-Endoperoxide Synthases / Q000378:metabolism; D011493:Protein Kinase C / Q000037:antagonists & inhibitors / Q000378:metabolism; D047428:Protein Kinase Inhibitors / Q000494:pharmacology; D051381:Rats; D017208:Rats, Wistar; D015398:Signal Transduction / Q000187:drug effects*; D010738:Type C Phospholipases / Q000378:metabolism
D000470:Alkaloids; D053119:Benzophenanthridines; D047428:Protein Kinase Inhibitors; D004970:Estrone; D009569:Nitric Oxide; D011464:Epoprostenol; C016299:chelerythrine; D052248:Nitric Oxide Synthase Type I; D011451:Prostaglandin-Endoperoxide Synthases; D019869:Phosphatidylinositol 3-Kinases; D011493:Protein Kinase C; D010738:Type C Phospholipases